- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Raytel sells Florida clinic
Raytel has completed the sale of its wholly owned subsidiary, the Heart Institute of Port St. Lucie, to a new company composed of physicians practicing at the clinic. Under the agreement Raytel received $8 million. Raytel acquired the clinic in August
Raytel has completed the sale of its wholly owned subsidiary, the Heart Institute of Port St. Lucie, to a new company composed of physicians practicing at the clinic. Under the agreement Raytel received $8 million. Raytel acquired the clinic in August 1997 as part of its purchase of Cardiovascular Ventures, which also owned and operated cardiovascular diagnostic facilities in Texas and Louisiana. The divestiture is part of Raytel's strategy of focusing on its core business: providing cardiac monitoring and testing services and operating cardiac diagnostic facilities and diagnostic imaging centers.
© 2001 Miller Freeman Inc.
3/28/01, Issue # 1506, page 6.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.
